A Review on Liposomes : A Promising Technique for Drug Delivery System

Authors

  • Akanksha S. Atole  Pharmaceutical Quality Assurance Department, Shankarrao Ursal College of Pharmaceutical Science & Research Centre Kharadi, Maharashtra, India
  • Vijaya U. Barge  Pharmaceutical Quality Assurance Department, Shankarrao Ursal College of Pharmaceutical Science & Research Centre Kharadi, Maharashtra, India

DOI:

https://doi.org//10.32628/IJSRST52310655

Keywords:

Liposomes, Microscopic, Drug Delivery, Versatile drug Vesicles, Cancer Therapy.

Abstract

This Liposomes are microscopic (unilamellar or multilamellar) vesicles. Liposomes have been considered promising and versatile drug vesicles. Compared with traditional drug delivery systems, liposomes exhibit better properties, including site-targeting, sustained or controlled release, protection of drugs from degradation and clearance, superior therapeutic effects, and lower toxic side effects. Given these merits, several liposomal drug products have been successfully approved and used in clinics over the last couple of decades. Currently, a number of liposomal formulations are on the marker for cancer treatment and many more are in pipe line. This review discusses about the liposome components, methods of preparation, drug encapsulation mechanism and the potential therapeutic applications of liposomes in cancer therapy. The term liposome means lipid body. It has been derived on the basis of name of subcellular particles, ribosome. Liposomes were first made by A.D Bangham in early 1960s. Their size ranges from 25 to 500 nm. This paper summarizes exclusively scalable techniques and focuses on limitations in respect to industrial applicability and regulatory requirements concerning liposomal drug formulations based on FDA and EMEA documents.

References

  1. FDA U. Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labelling Documentation. Guid. Ind. 2018 Apr.
  2. Mazur F, Bally M, Städler B, Chandrawati R. Liposomes and lipid bilayers in biosensors. Advances in colloid and interface science. 2017 Nov 1;249:88-99.
  3. Düzgüneş N, Gregoriadis G. Introduction: the origins of liposomes: Alec Bangham at Babraham. In Methods in enzymology 2005 Jan 1 (Vol. 391, pp. 1-3). Academic Press.
  4. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. Journal of molecular biology. 1964 Jan 1;8(5):660-IN10.
  5. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug discovery today. 2003 Dec 15;8(24):1112-20.
  6. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. Journal of controlled release. 1998 Apr 30;53(1-3):275-9.
  7. Allen TM. Liposomes: opportunities in drug delivery. Drugs. 1997 Oct;54:8-14.
  8. Zhang M, Gao S, Yang D, Fang Y, Lin X, Jin X, Liu Y, Liu X, Su K, Shi K. Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. Acta Pharmaceutica Sinica B. 2021 Aug 1;11(8):2265-85.
  9. Atrooz OM. Effects of alkylresorcinolic lipids obtained from acetonic extract of Jordanian wheat grains on liposome properties. Int J Biol Chem. 2011;5(5):314-21.
  10. Benech RO, Kheadr EE, Laridi R, Lacroix C, Fliss I. Inhibition of Listeria innocua in cheddar cheese by addition of nisin Z in liposomes or by in situ production in mixed culture. Applied and environmental microbiology. 2002 Aug;68(8):3683-90.
  11. Shehata T, Ogawara KI, Higaki K, Kimura T. Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. International journal of pharmaceutics. 2008 Jul 9;359(1-2):272-9.
  12. Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2007 May 1;1768(5):1121-7.
  13. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A: Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005, 16:691–707.
  14. Omri A, Suntres ZE, Shek PN: Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 2002, 64:1407–1413.
  15. Schiffelers RM, Storm G, Bakker-Woudenberg IA. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharmaceutical research. 2001 Jun; 18:780-7.
  16. Stano P, Bufali S, Pisano C, Bucci F, Barbarino M, Santaniello M, Carminati P, Luisi PL: Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method. J Liposome Res 2004, 14:87–109.
  17. Hemanthkumar M, Spandana V. Liposomal encapsulation technology a novel drug delivery system designed for ayurvedic drug preparation. IRJP. 2011;2(10):4-7.
  18. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR. The global burden of cancer 2013. JAMA oncology. 2015 Jul 1;1(4):505-27.
  19. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015 Mar;65(2):87-108.
  20. Bhardwaj A, Srivastava SK, Singh S, Arora S, Tyagi N, Andrews J, McClellan S, Carter JE, Singh AP. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget. 2014 Nov;5(22):11490.
  21. Tyagi N, Bhardwaj A, Singh AP, McClellan S, Carter JE, Singh S. p-21 activated kinase 4 promotes proliferation and survival of pancreatic cancer cells through AKT-and ERK-dependent activation of NF-κB pathway. Oncotarget. 2014 Sep;5(18):8778.
  22. Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh AP, Carter JE, Scammell JG, Fodstad Ø, Singh S. Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis. British journal of cancer. 2015 May;112(11):1772-81.
  23. Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh S, Andrews J, McClellan S, Wang B, Singh AP. MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and-independent pathways. British journal of cancer. 2015 Aug;113(4):660-8.
  24. MacDonald V. Chemotherapy: managing side effects and safe handling. The Canadian Veterinary Journal. 2009 Jun;50(6):665.
  25. Ramirez LY, Huestis SE, Yap TY, Zyzanski S, Drotar D, Kodish E. Potential chemotherapy side effects: what do oncologists tell parents? Pediatric blood & cancer. 2009 Apr;52(4):497-502.
  26. Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biological and pharmaceutical bulletin. 2013 May 1;36(5):715-8.
  27. Tyagi N, Rathore SS, Ghosh PC. Enhanced killing of human epidermoid carcinoma (KB) cells by treatment with ricin encapsulated into sterically stabilized liposomes in combination with monensin. Drug Delivery. 2011 Aug 1;18(6):394-404.
  28. Tyagi N, Rathore SS, Ghosh PC. Efficacy of liposomal monensin on the enhancement of the antitumour activity of liposomal ricin in human epidermoid carcinoma (KB) cells. Indian Journal of Pharmaceutical Sciences. 2013 Jan;75(1):16.
  29. Arora S, Tyagi N, Bhardwaj A, Rusu L, Palanki R, Vig K, Singh SR, Singh AP, Palanki S, Miller ME, Carter JE. Silver nanoparticles protect human keratinocytes against UVB radiation-induced DNA damage and apoptosis: potential for prevention of skin carcinogenesis. Nanomedicine: Nanotechnology, Biology and Medicine. 2015 Jul 1;11(5):1265-75.
  30. Alving CR. Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents. Advanced Drug Delivery Reviews. 1988 Oct 1;2(1):107-28.
  31. Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. Nature. 1974 Nov 15;252(5480):252-.
  32. Deamer D, Uster P. Liposome preparation methods and monitoring liposome fusion. Introduction of Macromolecules into viable Mammalian Cells, Alan R. Liss, New York. 1980:205.
  33. De Marie S, Jankengt R, Bakker-Woudenberg IA. Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy. 1994 May 1;33(5):907-16.
  34. Lasic DD, Papahadjopoulos D. Liposomes revisited. Science. 1995 Mar 3;267(5202):1275-6.
  35. Emanuel N, Kedar E, Bolotin EM, Smorodinsky NI, Barenholz Y. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes. Pharmaceutical research. 1996 Mar; 13:352-9.
  36. Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chemical reviews. 2015 Oct 14;115(19):10938-66.
  37. Kim T, Kim J, Kim S. Extended-release formulation of morphine for subcutaneous administration. Cancer chemotherapy and pharmacology. 1993 May; 33:187-90.
  38. Fan Y, Marioli M, Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. Journal of pharmaceutical and biomedical analysis. 2021 Jan 5; 192:113642.
  39. Wang N, Wu T, Wang T. Liposomes used as a vaccine adjuvant-delivery system. InLiposomes 2017 Oct 25. IntechOpen.
  40. Barenholz YC. Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of controlled release. 2012 Jun 10;160(2):117-34.
  41. Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, Deng Y. A review on phospholipids and their main applications in drug delivery systems. Asian journal of pharmaceutical sciences. 2015 Apr 1;10(2):81-98.
  42. Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H. Preparation, characterization and applications of liposomes: state of the art. Journal of colloid Science and Biotechnology. 2012 Dec 1;1(2):147-68.
  43. Marqués-Gallego P, de Kroon AI. Ligation strategies for targeting liposomal nanocarriers. BioMed research international. 2014 Jul 14;2014.
  44. Farge E, Devaux PF. Shape changes of giant liposomes induced by an asymmetric transmembrane distribution of phospholipids. Biophysical journal. 1992 Feb 1;61(2):347-57.
  45. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. International Scholarly Research Notices. 2012;2012.
  46. Ellens H, Bentz J, Szoka FC. Destabilization of phosphatidylethanolamine liposomes at the hexagonal phase transition temperature. Biochemistry. 1986 Jan 1;25(2):285-94.
  47. Magarkar A, Dhawan V, Kallinteri P, Viitala T, Elmowafy M, Róg T, Bunker A. Cholesterol level affects surface charge of lipid membranes in saline solution. Scientific reports. 2014 May 21;4(1):5005.
  48. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochemical Journal. 1980 Feb 15;186(2):591-8.
  49. Lasic DD. On the thermodynamic stability of liposomes. Journal of colloid and interface science. 1990 Nov 1;140(1):302-4.
  50. Mayer LD, Hope MJ, Cullis PR, Janoff AS. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1985 Jul 11;817(1):193-6.
  51. Vyas SP, Khar RK. Targeted & controlled drug delivery: novel carrier systems. CBS publishers & distributors; 2004.
  52. Deamer D, Bangham AD. Large volume liposomes by an ether vaporization method. Biochimica et Biophysica Acta (BBA)-Nucleic Acids and Protein Synthesis. 1976 Sep 7;443(3):629-34.
  53. Schieren H, Rudolph S, Finkelstein M, Coleman P, Weissmann G. Comparison of large unilamellar vesicles prepared by a petroleum ether vaporization method with multilamellar vesicles: ESR, diffusion and entrapment analyses. Biochimica et Biophysica Acta (BBA)-General Subjects. 1978 Aug 3;542(1):137-53.
  54. Himanshu A, Sitasharan P, Singhai AK. Liposomes as drug carriers. IJPLS. 2011;2(7):945-51.
  55. Kataria S, Sandhu P, Bilandi AJ, Akanksha M, Kapoor B. Stealth liposomes: a review. International journal of research in ayurveda & pharmacy. 2011 Sep 1;2(5).
  56. Shaheen SM, Shakil Ahmed FR, Hossen MN, Ahmed M, Amran MS, Ul-Islam MA. Liposome as a carrier for advanced drug delivery. Pak J Biol Sci. 2006;9(6):1181-91.
  57. Daemen T, Hofstede G, Ten Kate MT, Bakker‐Woudenberg IA, Scherphof GL. Liposomal doxorubicin‐induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages. International journal of cancer. 1995 May 29;61(5):716-21.
  58. Kirby CJ, Gregoriadis G. A simple procedure for preparing liposomes capable of high encapsulation efficiency under mild conditions. InLiposome technology 2019 Jul 23 (pp. 19-27). CRC Press.
  59. Alpes H, Allmann K, Plattner H, Reichert J, Rick R, Schulz S. Formation of large unilamellar vesicles using alkyl maltoside detergents. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1986 Nov 17;862(2):294-302.
  60. Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. International scholarly research notices. 2014;2014.
  61. Bozzuto G, Molinari A. Liposomes as nanomedical devices. International journal of nanomedicine. 2015 Feb 2:975-99.
  62. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale research letters. 2013 Dec; 8:1-9.
  63. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1993 Sep 19;1151(2):201-15.
  64. Lasic DD, Frederik PM, Stuart MC, Barenholz Y, McIntosh TJ. Gelation of liposome interior A novel method for drug encapsulation. FEBS letters. 1992 Nov 9;312(2-3):255-8.
  65. Qiu L, Jing N, Jin Y. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method. International journal of pharmaceutics. 2008 Sep 1;361(1-2):56-63.
  66. Maurya P. PHARMACEUTICAL LIPOSOMAL DRUG DELIVERY: A COMPLETE REVIEW OF NEW DELIVERY SYSTEM.
  67. Jain NK, editor. Controlled and novel drug delivery. New Delhi: CBS publishers & distributors; 1997.
  68. Kersten GF, Crommelin DJ. Liposomes and ISCOMS as vaccine formulations. Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes. 1995 Jul 17;1241(2):117-38.
  69. Horton K. Disertation for degree of Advanced Studies in Chemical Engineering. Universitat Rovira I Virgili. 2003.
  70. Gosavi AA, Salunkhe KK. Updated Review On: Liposome.
  71. Sharma A, Straubinger RM. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharmaceutical research. 1994 Jun; 11:889-96.
  72. Szoka FC. Liposomal drug delivery: current status and future prospects. Membrane fusion. 2019 Nov 14:845-90.
  73. Vingerhoeds MH, Storm G, Crommelin DJ. Immunoliposomes in vivo. Immunomethods. 1994 Jun 1;4(3):259-72.
  74. Vyas SP, Khar RK. Targeted & controlled drug delivery: novel carrier systems. CBS publishers & distributors; 2004.
  75. Banerjee R, Tyagi P, Li S, Huang L. Anisamide‐targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. International journal of cancer. 2004 Nov 20;112(4):693-700.
  76. Gill PS, Espina BM, Muggia F, Cabriales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. Journal of clinical Oncology. 1995 Apr;13(4):996-1003.
  77. Guaglianone P, Chan K, DelaFlor-Weiss E, Hanisch R, Jeffers S, Sharma D, Muggia F. Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome). Investigational new drugs. 1994 Jun; 12:103-10.
  78. Eckardt JR, Campbell E, Bums HA, Weiss GR, Rodriguez GI, Fields SM, Thurman AM, Peacock NW, Cobb P, Rothenberg MA, Ross ME. A phase II trial of DaunoXome, liposome-encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. American journal of clinical oncology. 1994 Dec 1;17(6):498-501.
  79. Schurmann D, Dormann A, Grunewald T, Ruf B. Successful treatment of AIDS-related pulmonary Kaposi's sarcoma with liposomal daunorubicin. European Respiratory Journal. 1994 Apr 1;7(4):824-5.
  80. New RR, Chance ML, Thomas SC, Peters W. Antileishmanial activity of antimonials entrapped in liposomes. Nature. 1978 Mar 2;272(5648):55-6.
  81. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale research letters. 2013 Dec; 8:1-9.
  82. Svenson CE, Popescu MC, Ginsberg RC. Liposome treatments of viral, bact and protozoal infections. Crit Rev Microbiol. 1988;15: S1-31.
  83. Storm G, Roerdink FH. A Steerenberg, P.; De Jong, WH; Crommelin, DJ Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res. 1987; 47:3366-72.
  84. Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. RETRACTED ARTICLE: Preparation and in vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymers. International journal of nanomedicine. 2012 Feb 1:511-26.
  85. Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale research letters. 2012 Dec; 7:1-3.
  86. Valizadeh A, Mikaeili H, Samiei M, Farkhani SM, Zarghami N, Kouhi M, Akbarzadeh A, Davaran S. Quantum dots: synthesis, bioapplications, and toxicity. Nanoscale research letters. 2012 Dec; 7:1-4.
  87. Akbarzadeh A, Samiei M, Joo SW, Anzaby M, Hanifehpour Y, Nasrabadi HT, Davaran S. RETRACTED ARTICLE: Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. Journal of nanobiotechnology. 2012 Dec;10(1):1-3.
  88. Du S, Deng Y. Studies on the encapsulation of oxymatrine into liposomes by ethanol injection and pH gradient method. Drug development and industrial pharmacy. 2006 Jan 1;32(7):791-7.
  89. Chou H, Lin H, Liu JM. A tale of the two PEGylated liposomal doxorubicins. OncoTargets and therapy. 2015 Jul 13:1719-20.
  90. Berger JL, Smith A, Zorn KK, Sukumvanich P, Olawaiye AB, Kelley J, Krivak TC. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. OncoTargets and therapy. 2014 Aug 8:1409-13.
  91. Fantini M, Gianni L, Santelmo C, Drudi F, Castellani C, Affatato A, Nicolini M, Ravaioli A. Lipoplatin treatment in lung and breast cancer. Chemotherapy research and practice. 2011;2011.
  92. Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. Journal of Thoracic Oncology. 2008 Jun 1;3(6): S164-70.
  93. Lasic DD. Novel applications of liposomes. Trends in biotechnology. 1998 Jul 1;16(7):307-21.
  94. Kapoor M, Lee SL, Tyner KM. Liposomal drug product development and quality: current US experience and perspective. The AAPS journal. 2017 May; 19:632-41.

International Journal of Scientific Research in Science and Technology

Downloads

Published

2023-12-30

Issue

Volume 10, Issue 6, November-December-2023

Section

Research Articles

License

Copyright (c) IJSRST

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Akanksha S. Atole, Vijaya U. Barge, " A Review on Liposomes : A Promising Technique for Drug Delivery System, International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011, Volume 10, Issue 6, pp.439-461, November-December-2023. Available at doi : https://doi.org/10.32628/IJSRST52310655